Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
Director comp.
|
|
MoonLake Immunotherapeutics
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/11/2022 |
8-K
| Amended existing or entered into new employment agreement with an officer, Director compensation was amended/approved|
Docs:
|
"Memorandum and Articles of Association of MoonLake Immunotherapeutics",
"Amended and Restated Shareholders’ Agreement, by and among MoonLake Immunotherapeutics, MoonLake Immunotherapeutics AG and the investors signatory thereto",
"Amended and Restated Registration Rights Agreement, by and among the MoonLake Immunotherapeutics, Helix Holdings LLC and the holders signatory thereto",
"Form of Subscription Agreement",
"MOONLAKE IMMUNOTHERAPEUTICS 2022 EQUITY INCENTIVE PLAN",
"Letter Agreement, among Helix Acquisition Corp., Helix Holdings LLC and each of the officers and directors of Helix (incorporated by reference to of Helix’s Form 8-K, filed with the SEC on October 22, 2020)",
"Code of Business Conduct and Ethics",
"Subsidiaries of MoonLake Immunotherapeutics",
"MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.",
"MoonLake Immunotherapeutics unaudited pro forma condensed combined balance sheet as of December 31, 2021 and the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2021" |
|
|
|